open access | register
Medical Conferences

Medical Conferences

  • Conference Reports
  • Conference Proceedings
  • Specialties
    • Cardiology
    • Dermatology
    • Endocrinology
    • Gastroenterology
    • Haematology
    • Nephrology
    • Neurology
    • Oncology
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Urology
  • Multimedia
    • Podcast channel
    • Video channel
  • About
    • 2025 Medicom Conference Planning
    • About Conference Proceedings
    • Webinar
Home > Oncology > ASCO 2023

ASCO 2023


American Society of Clinical Oncology
02–06 June 2023
Chicago, IL, USA
  • Table of contents
  • Colophon

Table of Contents



Featured articles

Real-world data support new SOC in patients with SCLC

Expert
Prof. Nicolas Girard, Institut Curie, Paris, France

Letter from the Editor

Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg

What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?

Expert
Dr Cha Len Lee, University of Toronto, Canada

ASCO 2023 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom

Colorectal Cancer

7-year outcomes of PRODIGE 23 trial

Presented By
Prof. Thierry Conroy, Institut de Cancérologie de Lorraine, France

Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer

Presented By
Dr Lars Hendrik Jensen, University of Southern Denmark, Denmark

De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior

Presented By
Dr Deborah Schrag, Memorial Sloan Kettering Cancer Center, NY, USA

Breast Cancer

SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer

Presented By
Prof. Gabe Sonke, Netherlands Cancer Institute, the Netherlands

Adjuvant ribociclib improves invasive DFS in early breast cancer

Presented By
Prof. Dennis Slamon, David Geffen School of Medicine, CA, USA

Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer

Presented By
Dr Hanna Huebner, Erlangen University Hospital, Germany

Lung Cancer

Adding pembrolizumab to perioperative chemotherapy improves EFS in early-stage NSCLC

Presented By
Prof. Heather Wakelee, Stanford University, CA, USA

TTFields therapy: a new treatment modality for metastatic NSCLC

Presented By
Prof. Ticiana Leal, Emory University, GA, USA

Adding chemotherapy to EGFR TKI does not improve OS in advanced EGFR-mutated NSCLC

Presented By
Dr Shintaro Kanda, Shinshu University, Japan

Upper GI Cancer

No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX

Presented By
Prof. Knut Labori, Oslo University Hospital, Norway

AI detects gastric cancer with high accuracy in common blood tests

Presented By
Mr Tsz Chun Bryan Wong, Hong Kong University of Science and Technology, Hong Kong

Melanoma

Response-directed treatment personalisation in stage III melanoma

Presented By
Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By
Prof. Georgina Long, University of Sydney, Australia

GU Cancers

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By
Prof. Karim Fizazi, Institute Gustave Roussy, France

Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer

Presented By
Dr Yohann Loriot, Gustave Roussy Cancer Institute, France

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By
Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By
Dr Enrico Grande, MD Anderson Cancer Center, Spain

Miscellaneous

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By
Dr Philipp Harter, Kliniken Essen-Mitte, Germany

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By
Prof. Alex Herrera, City of Hope Medical Center, CA, USA

Vorasidenib successfully targets IDH1/2-mutated glioma

Presented By
Dr Ingo Mellinghoff, Memorial Sloan Kettering Cancer Center, NY, USA

ASCO Interviews

IMbrave050: Adjuvant atezolizumab plus bevacizumab provides landmark recurrence-free survival for HCC

Expert
Prof. Masatoshi Kudo, Kindai University, Japan

What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?

Expert
Dr Cha Len Lee, University of Toronto, Canada
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com